Targeting the constitutively expressed receptor, CD25, to neutralize Treg is limited by the challenge of the transient expression on Tc and/or Tconv during activation-induced upregulation, including those vaccine-associated effector T cells that carry out anti-tumor responses. This evidence concerns the gene IL2RA and neoplasm.